StockData
CTORNasdaqPharmaceutical PreparationsFiscal year ends September 30

CITIUS ONCOLOGY, INC.

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.71−0.06 (-7.49%)

Close on Oct 19, 2026

Market cap
$76.65M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Dec 22, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q3 FY2026
Ended Jun 30, 2026
Aug 14, 2026During market hours$1.50M$-0.08–
Q2 FY2026
Ended Mar 31, 2026
May 15, 2026During market hours$1.70M$-0.27–
Q1 FY2026
Ended Dec 31, 2025
Feb 13, 2026Before market open$3.90M$-0.06–
Q4 FY2025
Ended Sep 30, 2025
Dec 23, 2025During market hours–––
Q3 FY2025
Ended Jun 30, 2025
Aug 12, 2025During market hours–$-0.08–
Q2 FY2025
Ended Mar 31, 2025
May 14, 2025During market hours–$-0.11–

Press releases

Announcements Citius Oncology filed with the SEC